Ecofibre (ASX:EOF) share price plummets 24%. Here's why

The Ecofibre Ltd (ASX: EOF) share price has plummeted in mid-morning trade following the company's release of a first quarter update.

| More on:
Falling asx share price represented by man in chinos falling suspended in mid-air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ecofibre Ltd (ASX: EOF) share price has plummeted in mid-morning trade following the company's release of a first quarter update. At the time of writing, the Ecofibre share price has dropped 24.49% to $1.85.

What's pushing the Ecofibre share price lower?

The Ecofibre share price is in freefall today after the company reported disappointing results marked by severe impacts of COVID-19 for the quarter ending 30 September.

The company said that cash flow and revenue are on track, however a loss is expected to be incurred in H1 FY21. Ecofibre advised the setback is due to the pandemic causing political and social disruption to retail in the United States.

Revenue for the first three months of FY21 came in at $7.1 million, down 51% on the prior corresponding period. As trading conditions remain difficult, the company is forecasting to break even in FY21.

On a positive note, Ecofibre said that it is starting to see early signs of recovery in its US independent pharmacy segment. The company is further developing its relationship with customers through its Ananda Health business, supporting a return of normal operations. Engagement and education to its customers are seen as key pillars to drive future growth.

The company recorded cash on hand of $15.6 million, as compared to $18.3 million at the end of June. Limited further investment is expected in FY21 to preserve capital until the business can see improvements in the economic climate.

New developments

At the end of the quarter, shipping commenced of Ecofibre's batch of Balans Labs products to CVS Health Corp (NYSE: CVS) stores. The range of topical hemp products will be distributed to over 4,000 retail locations across the United States. Additional expansion plans are underway to provide more items.

Completed acquisition

The company stated that the acquisition of TexInnovate in August 2020 has been completed and is progressing well. TexInnovate, now renamed to Hemp Black, produced revenues of $2.6 million for the quarter. The sales were split between face mask sales and revenues from the original TexInnovate business.

Hemp Black said it has customers in segments including medical yarns, high performance polymers, outdoor turf, furniture applications and personal protective equipment (PPE). The company is focused on supplying a target segment that will exist over the medium term.

Management commentary

Ecofibre CEO, Eric Wang, commented on the poor performance encountered for the quarter. He said:

Trading conditions remain difficult in the US CBD market and the demand for PPE has reduced. As discussed last quarter, we are reshaping our business priorities to adjust for changes in purchasing behaviours with our distributors and independent pharmacies.

We are working to ensure we retain and grow our leadership position in the US retail pharmacy channel. There is strong confidence in the long-term future of hemp-derived CBD in this channel as it will be the preferred channel for patients with health conditions that are advised by pharmacists and medical practitioners.

Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends CVS Health. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

An old-fashioned panel of judges each holding a card with the number 10
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the trading week this Friday.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Share Market News

Macquarie says this top ASX tech stock could rise 15%

Let's see what the broker is saying about this stock.

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Up 680% since July, here's why 2025 was a breakout year for this hot ASX stock

With consistent contract wins, FDA clearance, and backing from Pro Medicus, 4D Medical is showing that there is a commercial…

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Collins Foods, Monash IVF, Premier Investments, and Step One shares are tumbling today

These shares are ending the week in the red. But why?

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Share Gainers

4 ASX 200 stocks smashing the benchmark this week

Investors have been piling into these four ASX 200 stocks this week. Let’s see why.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Bendigo Bank, NextDC, Nuix, and Vulcan Energy shares are rising today

These shares are ending the week on a high. But why?

Read more »

Time to sell ASX 200 shares written on a clock.
Share Market News

Sell alert! Why analysts are calling time on these 2 ASX 300 stocks

Two leading investment experts recommend selling these ASX 300 shares today. But why?

Read more »